Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7641-7650 Newer>

The Motley Fool July 13, 2011	Lincare Holdings Earnings Preview Lincare Holdings, provider of oxygen and other respiratory therapy services to patients, is looking to meet the Street's expectations for the third consecutive quarter on Monday.
The Motley Fool July 13, 2011	Immucor Earnings Preview After beating estimates last quarter by 5 cents, Immucor has set the standard for itself this Monday, July 18.
The Motley Fool July 13, 2011	ICU Medical Earnings Preview Medical systems maker ICU Medical will unveil its latest earnings on Monday, July 18. Investors never know what to expect for the company, as it has wavered between topping and missing analysts estimates during the past fiscal year.
The Motley Fool July 13, 2011 David Williamson	Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of.
The Motley Fool July 13, 2011 Brian Orelli	2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin.
The Motley Fool July 13, 2011 Brian Orelli	BioSante Is Ready for Some Action Investors are opening positions in BioSante in anticipation of the release of company data from two clinical trials for its female sexual-dysfunction treatment, LibiGel, by the end of the year.
The Motley Fool July 13, 2011 Arundhati Parmar	FDA OKs Study Design on Medtronic Product That Firm Is Bullish On The product is the Simplicity catheter-based system to treat hypertension, or high blood pressure.
The Motley Fool July 12, 2011 Brian Orelli	Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool July 12, 2011 Tracy Staton	Gilead First to Jump Into AIDS Patent Pool Gilead Sciences has broken the ice on the AIDS drug patent pool.
<Older 7641-7650 Newer> Return to current articles.